Ocrelizumab | 合法藥品大搜索

Ocrelizumab,soldunderthebrandnameOcrevus,isapharmaceuticaldrugforthetreatmentofmultiplesclerosis(MS).Itisahumanizedanti-CD20monoclonal​ ...

Anti-CD20 monoclonal antibody

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody.[6] It targets CD20 marker on B lymphocytes and is an immunosuppressive drug.[8] Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.[8]

It was approved by the US Food and Drug Administration (FDA) in March 2017,[9] and the first FDA approved drug for the primary progressive form of MS; it was discovered and developed and is marketed by Hoffmann–La Roches subsidiary Genentech under the trade name Ocrevus.[10][6] With the approval, the FDA also required the company to conduct several Phase IV clinical trials to better understand whether the drug is safe and effective in young people, cancer risks, and effects on pregnant women and children they might ...